eXoZymes, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael Heltzen
- Full Time Employees
- 32
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 750 Royal Oaks Drive Monrovia CA United States of America 91016
- IPO Date
- Nov 13, 2024
- CIK
- 0002010788
- Website
- exozymes.com
- Similar Companies
- Business
- eXoZymes, Inc. (Nasdaq: EXOZ) develops a cell-free biomanufacturing platform utilizing AI-engineered exozymes to produce high-purity small-molecule chemicals from affordable feedstocks such as sugar and biomass; the platform comprises modular enzyme cascades that perform biocatalytic conversions for applications in nutraceuticals, pharmaceuticals, biofuels, fragrances, and specialty chemicals. Core products and services include biosolutions for producing natural compounds like nicotinamide riboside (NCT) and its patentable analogs targeting metabolic diseases such as obesity, non-intoxicating cannabinoids for medicinal uses, santalene (sandalene) for fragrances with nutraceutical and pharmaceutical potential, active pharmaceutical ingredients (APIs), food additives, colors, and novel compounds; the company achieves over 95% purity with a roadmap to 99.5% pharmaceutical-grade quality, enabling scalable, sustainable production that overcomes limitations of traditional petrochemical and cell-based synthetic biology methods. Founded in 2014 and headquartered in Monrovia, California, eXoZymes operates primarily in the United States with a focus on biotechnology and healthcare sectors, serving markets including nutraceuticals ($200 billion global TAM), pharmaceuticals (over $100 billion for metabolic treatments), and biofuels such as sustainable aviation fuel; the company employs around 31 people and maintains a capital-light model with 11-50 employees. In February 2025, the company changed its name from Invizyne Technologies, Inc. to eXoZymes, Inc. to reflect its exozyme technology; recent developments include forming the NCTX spinout to commercialize NCT for supplements with plans to scale production by end-2026, achieving breakthroughs like 4 grams of NCT at over 99% purity using AI-driven processes, receiving a $3 million National Science Foundation grant as part of a $9 million Meta-PURE initiative to develop a cell-free ATP module and santalene production, advancing cannabinoid programs with U.S. government sponsorship and joint venture discussions amid new federal laws separating intoxicating and non-intoxicating cannabinoids, promoting Tyler Korman to Chief Scientific Officer, and reporting Q3 2025 net loss of $2.29 million with $5.1 million cash supporting operations into Q2 2026 while exploring partnerships and potential capital raises.
Company News
eXoZymes Q2 Earnings Call Highlights
eXoZymes Q2 Earnings Call Highlights
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
eXoZymes (NASDAQ:EXOZ) Shares Down 1.1% – What’s Next?
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
eXoZymes Inc. Announces Closing of $6 Million Public Offering
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
Head-To-Head Analysis: eXoZymes (NASDAQ:EXOZ) & Curis (NASDAQ:CRIS)
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
Critical Review: eXoZymes (NASDAQ:EXOZ) vs. Disc Medicine (NASDAQ:IRON)
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run